http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3845222-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a04855ca2e7d029c9f7204da5203056f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2068 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate | 2020-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da7cfbb9cbc1ba17890b776edc794448 |
| publicationDate | 2021-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3845222-A1 |
| titleOfInvention | Microencapsulated formulation comprising diosmin, troxerutin and coumarins, compositions thereof and use thereof for the treatment of circulatory disorders |
| abstract | The present invention relates to a microencapsulated formulation with a coating matrix comprising at least one lipid, preferably a phospholipid, wherein said formulation comprises: (a) diosmin (b) troxerutin and (c) coumarins. Furthermore, the present invention relates to compositions comprising said microencapsulated formulation and, optionally, (d) vitamin C. Lastly, the present invention relates to the use of said microencapsulated formulations and the compositions thereof for the treatment of disorders of the circulatory system, preferably of a chronic venous insufficiency or haemorrhoidal disease or edematous fibrosclerotic panniculopathy (PEFS) or lymphedema or trauma or endothelial dysfunction. |
| priorityDate | 2019-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 89.